

Additional Milestones Achieved for Theratechnologies in Second Quarter 2007

- Positive TH9507 Phase 3 results presented at CROI and ENDO meetings
- Last patient treated in the extension phase of the first Phase 3 trial
- Confirmatory Phase 3 trial under way in Europe and North America
- Paul Pommier Assumes Chairman's Role at Annual Meeting of Shareholders
- Named "Biotech Company of the Year" by BIOTECCanada

Montréal, July 10, 2007 – Theratechnologies (TSX: TH) announced today its financial results for the second quarter ended May 31, 2007 and reviewed recent highlights.

"Several important milestones have added fuel to the strong momentum gained in the first quarter," said Yves Rosconi, President and Chief Executive Officer. "Building on the positive Phase 3 clinical trial results announced last December, we were able to release additional positive data at scientific meetings in the second quarter," commented Mr. Rosconi. "In addition to the data supporting our development plans for TH9507, we believe that the metabolic parameters known to be risk factors for cardiovascular diseases may be lowered in HIV-infected patients using TH9507," noted Mr. Rosconi.

"As the data come out, it is becoming increasingly clear that TH9507 has potential as a treatment for excess visceral fat accumulation in HIV patients and has potential advantages over other approaches being developed," Mr. Rosconi continued. "For the balance of the year, we are looking forward to:

- the release of additional 26-week data next week at an HIV Lipodystrophy conference in Sydney, Australia;
- the release of the 52-week data from our first Phase 3 study in the fall 2007; and
- the steady progress on the confirmatory Phase 3 trial."

"We have a strong balance sheet and a clear business plan so the Company is enthusiastic about its future," Mr. Rosconi concluded.

Forward-looking statements

This press release contains forward-looking statements reflecting the Company's current expectations regarding the TH9507 Phase 3 clinical program including, among others, the nature of the results and their timing, and the future development of the Company. By their very nature, these statements involve uncertainties and inherent risks, both general and specific, which give rise to the possibility that predictions will not materialize. We therefore caution investors against placing undue reliance on these statements. We refer you to pages 15 to 19 of the 2006 Annual Information Form, which contain a more exhaustive analysis of the risks and uncertainties connected to the business of the Company. We have no obligation whatsoever to update forward-looking statements and we do not undertake to do so.

Recent highlights:

Positive phase 3 clinical results presented at CROI and ENDO meetings

Dr. Steve Grinspoon, Associate Professor of Medicine, Harvard Medical School and lead investigator for the TH9507 trial in the United States presented Phase 3 results at two prestigious conferences this past quarter: the 14th Conference on Retroviruses and Opportunistic Infections (CROI) and the 89th annual meeting of the Endocrinology Society (ENDO).

At CROI, Dr. Grinspoon discussed the Phase 3 results announced in December. In summary, the Phase 3 study was powered to detect an 8% reduction in visceral adipose tissue (VAT) versus placebo. After 26 weeks, patients on TH9507 achieved a 15% reduction in VAT versus baseline and a 20% difference versus placebo. In addition, TH9507 was shown to be well tolerated by patients.

At ENDO, Dr. Grinspoon elaborated further on the Phase 3 results discussing the beneficial effects of TH9507 on key metabolic parameters known to be risk factors for cardiovascular diseases, suggesting that strategies using a growth hormone releasing factor may lower cardiovascular risk in HIV infected patients.

Last patient treated in the extension phase of the first Phase 3 trial

In May 2007, the last patient had completed 52 weeks of treatment in the extension phase of the first Phase 3 clinical study testing TH9507. The objective of the extension phase of the study is to obtain safety information with long-term use of TH9507. The Company expects to discuss the top-line 52 week results at a venue to be determined in the fall 2007.

Second Confirmatory Phase 3 trial under way in Europe and North America

The confirmatory Phase 3 trial is ongoing. The protocol for this second Phase 3 trial was reviewed by the US FDA under the Special Protocol Assessment (SPA) process last August. The end of enrolment is expected early in the fall of 2007.

Theratechnologies has obtained regulatory approval in five European countries for its confirmatory Phase 3 trial. Patients are being enrolled for the study in Belgium, France, Italy, Spain and the United Kingdom. North American recruitment previously began in the United States in January and Canadian recruitment began in May.

Shareholders Welcome Paul Pommier as New Company Chairman

At the Theratechnologies Shareholder Meeting this past March, the Company's Chairman, Mr. A. Jean de Grandpré, announced his retirement as chairman of the Board after ten years of distinguished service. Several shareholders took the opportunity to pay tribute to Mr. de Grandpré at the meeting, who remains a member of the Board of Directors. Mr. Pommier, former investment banker with National Bank Financial and long-time member of the Board of Directors, has assumed the Chairman's position.

Biotech of the Year Award

Theratechnologies was recognized this year by winning the "Biotech Company of the Year" award presented by BIOTECanada. This award recognizes the Canadian biotech company that has distinguished itself from its peers with strong overall performance as a company, demonstrated leadership and significant achievement over the last year. BIOTECanada is the national industry-funded association representing the broad spectrum of biotech constituents including emerging, established and related service companies in the health, agricultural, and industrial sectors.

MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER

Revenues

Consolidated revenues for the three-month period ended May 31, 2007 increased to \$805,000 compared to \$395,000 in 2006. For the six-month period ended May 31, 2007, consolidated revenues were \$1,092,000 compared to \$870,000 for the same period in 2006. Revenues are mainly composed of interest from investments. The increase in interest revenue was due to higher liquidity balances in fiscal 2007 compared to 2006.

R&D activities

Consolidated research and development (R&D) expenditures, before tax credits, totalled \$6,576,000 for the second quarter of 2007, compared to \$5,361,000 in 2006. The R&D expenses for the six-month period ended May 31, 2007 amounted to \$14,676,000 compared to \$9,646,000 for the same period in 2006. The higher level of R&D expenditures in 2007 is essentially due to costs associated with the ongoing activities associated with the first Phase 3 study and the confirmatory Phase 3 study for TH9507.

Other expenses

For the second quarter of 2007, general and administrative expenses, selling and market development expenses, patents and amortization of other assets (SG&A) increased to \$2,550,000, compared to \$1,463,000 for the same period in 2006. For the six-month period ended May 31, 2007, the SG&A amounted to \$4,938,000 compared to \$3,276,000 for the same period in 2006. The increase is primarily attributable to increased foreign exchange losses, increased stock-based compensation expense and other expenses associated with the stock option program in fiscal 2007 compared to 2006. In addition, the higher expenses in 2007 reflect the Company's growth and increase in business development and commercialization activities.

Net results

Reflecting the changes in revenues and expenses described above, the Company recorded a second-quarter net loss of \$8,089,000 (\$0.15 per share), compared to \$6,221,000 (\$0.14 per share) for the same period in 2006. For the six-month period ended May 31, 2007, the loss was \$17,528,000 (\$0.35 per share), compared to losses of \$11,668,000 (\$0.29 per share) in 2006.

Quarterly financial information

The selected financial information provided below is derived from the Company's unaudited quarterly financial statements for each of the last eight quarters.

	2007				2006			2005
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3
Revenues	805	\$ 287	\$ 367	\$ 412	\$ 395	\$ 475	\$ 319	\$ 409
Operating loss	(8,089)	\$ (9,439)	\$ (6,942)	\$ (7,251)	\$ (6,221)	\$ (5,447)	\$ (5,580)	\$ (5,065)
Net loss	(8,089)	\$ (9,439)	\$ (6,942)	\$ (7,251)	\$ (6,221)	\$ (5,447)	\$ (5,651)	\$ (5,218)
Basic and diluted loss per share	(0.15)	\$ (0.20)	\$ (0.15)	\$ (0.16)	\$ (0.14)	\$ (0.15)	\$ (0.16)	\$ (0.15)

Financial position

Theratechnologies maintains a sound financial position. At May 31, 2007, liquidities amounted to \$76,305,000, which include cash and bonds of \$74,462,000 and tax credits receivable of \$1,843,000.

During the first quarter, the Company completed a public offering for the sale and issuance of 6,875,000 common shares, including those issued pursuant to the over-allotment option, for a cash consideration of \$57,750,000. Issue costs totaled \$3,238,000, resulting in net proceeds to the Company of \$54,512,000. During the first half 2007, the Company issued 765,534 common shares following the exercise of stock options, for cash proceeds of \$1,993,000. During the second quarter of 2007, the Company also issued 10,949 common shares to employees for a cash consideration of \$104,000 in connection with its share purchase plan.

For the three-month period ended May 31, 2007, the burn rate from operating activities, excluding changes in operating assets and liabilities, was \$7,467,000, compared to \$5,827,000 in 2006. For the six-month period ending May 31, 2007, the burn rate from operating activities, excluding changes in operating assets and liabilities, increased to \$15,029,000, compared to \$10,560,000 for the same period in 2006. The increased burn rate in 2007 is mostly the result of the planned increase in Phase 3 program activities which translated into higher R&D expenses as described above.

Changes in accounting policies

At the beginning of the fiscal year 2007, the Company adopted the following sections of the Canadian Institute of Chartered Accountants (CICA) Handbook: Section 1530 entitled "Comprehensive income", Section 3251 entitled "Equity", Section 3855 entitled "Financial instruments – Recognition and measurement", Section 3861 entitled "Financial Instruments – Presentation and Disclosure", and Section 3865 entitled "Hedges". The adoption of these standards had no material impact on the Company's operating results (see note 2 of the Consolidated Financial Statements).

Outstanding share data

Between June 1 and July 9, 2007, 48,333 options were exercised, at an average exercise price of \$3.87 per share, for cash proceeds of \$187,000. On July 9, 2007, the number of shares issued and outstanding was 54,475,175, while outstanding options granted under the stock option plan were 2,106,466.

Subsequent event

Sonomed Inc., formerly Andromed Inc., a public company in which Theratechnologies had invested, SND Energy Ltd. (a newly formed entity) and StoneBridge Merchant Capital Corp. entered into an Arrangement Agreement (the "Agreement"). The main purpose of the Agreement is to substantially distribute all of the assets of Sonomed to its shareholders. The shareholders of Sonomed have exchanged all of their common shares into units, each unit being comprised of one new common share and one new preferred share of Sonomed. Subsequently, all Sonomed new common shares have been exchanged on a one for one basis for SND Energy common shares, and all new preferred shares have been redeemed for a cash consideration of approximately \$0.10 per share. On July 3, 2007, the Company received a cash consideration of \$609,000 as a result of the redemption of the new preferred shares of Sonomed held by the Company.

Contractual obligations

Apart from the financings mentioned above, there were no material changes in contractual obligations during the semester, other than in the ordinary course of business.

Economic and industry factors

Economic and industry factors were substantially unchanged from those reported in the Company's 2006 annual report.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The most advanced program is TH9507, in Phase 3 clinical development in HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Additional information about Theratechnologies

Further information about Theratechnologies is available on the Company's website at www.theratech.com. Additional information is also available on SEDAR at www.sedar.com.

#

Information:

Andrea Gilpin
Executive Director, IR & Communications
Phone: 514-336-4804, ext. 205
agilpin@theratech.com

Luc Tanguay
Senior Executive Vice President and
Chief Financial Officer
Phone: 514-336-4804, ext. 204
ltanguay@theratech.com

Marie-Noël Colussi
Vice President, Finance
Phone: 514-336-4804, ext. 237
mncolussi@theratech.com